The study, published in CVIR Oncology, analyzed data from the CIRSE Registry for SIR-Spheres Therapy, known as CIRT, a Europe-wide observational study conducted in eight countries across 27 centers. Of the 1,036 patients enrolled with primary or secondary liver malignancies, the researchers focused on 169 adults whose liver metastases originated from neuroendocrine tumors, breast cancer, pancreatic cancer, or melanoma. All were treated with yttrium-90 resin microspheres, tiny radioactive spheres delivered through the hepatic artery that lodge in the small vessels feeding tumors and deliver high-dose internal radiation while sparing most healthy tissue.

The technical logic behind TARE is elegant. Unlike conventional external beam radiotherapy, which must pass through healthy tissue to reach its target, radioembolization exploits the fact that liver tumors draw their blood supply predominantly from the hepatic artery, while healthy liver tissue depends on the portal vein. Catheters threaded from a puncture in the groin or wrist guide the microspheres into the arteries supplying the tumors, where the beta radiation from yttrium-90, which travels only a few millimeters in tissue, kills cancer cells from within. Before treatment, teams perform careful mapping angiography and dosimetry, often using the body surface area method or a partition model, to calculate the activity to be injected and to avoid reflux of spheres into the stomach or bowel.

The survival results varied dramatically by tumor type, underscoring how different these diseases are. Patients with neuroendocrine tumors fared best, with a median overall survival of 33.3 months after treatment. Those with breast cancer liver metastases had a median survival of 10.7 months, while patients with melanoma reached 14.7 months. Pancreatic cancer, notoriously aggressive even when it has spread only to the liver, showed the poorest outcome at 5.6 months. Median follow-up ranged from 5.6 months in the pancreatic cohort to 19.3 months in the neuroendocrine group, and patients were enrolled between January 2015 and December 2017 with follow-up through the end of 2019.

Safety was the study’s most consistent message. Severe adverse events of grade three or higher, defined according to the standard CTCAE criteria, occurred in just 10 percent of all 169 patients. Procedure-related adverse events were predominantly mild to moderate, affecting roughly one in five neuroendocrine and breast cancer patients and only about six percent of those with pancreatic cancer or melanoma. Predefined serious events tracked in the registry included abdominal pain, fatigue, fever, nausea, vomiting, gastrointestinal ulceration, gastritis, and radiation cholecystitis, but these remained uncommon. For a therapy that delivers ionizing radiation directly into a vital organ, this safety profile across four very different tumor types is a notable result.

Perhaps the most scientifically intriguing findings came from the multivariable analysis, in which the researchers used Cox proportional hazards models to identify independent predictors of survival. Two laboratory-based markers emerged repeatedly. The Albumin-Bilirubin grade, or ALBI, which combines liver synthetic function with bile clearance, predicted worse overall survival in both the neuroendocrine and breast cancer cohorts, with hazard ratios above four. The Aspartate transaminase to Platelet Ratio Index, or APRI, a marker usually associated with liver fibrosis, predicted poorer survival in the neuroendocrine and melanoma cohorts. In melanoma patients the effect was striking: an APRI value above 0.40 carried a hazard ratio of 37.63 for death, an extraordinarily strong association. In breast cancer patients, an international normalized ratio above one and an elevated neutrophil-to-leukocyte ratio also predicted worse progression-free survival.

These biomarker findings carry practical weight. They suggest that the health of the underlying liver, and possibly the systemic inflammatory state reflected in blood counts, shapes how much patients benefit from internal radiation, and that the relevant markers differ by tumor type. The authors argue this supports individualized patient assessment that incorporates both the histology of the metastases and routine laboratory evaluation. It also hints that simple blood tests available before treatment could help clinicians select which patients are most likely to benefit, an increasingly important question as liver-directed therapies proliferate.

Context matters for interpreting the survival numbers. For neuroendocrine liver metastases, which develop in up to 80 percent of patients with these tumors, the 33.3 month median survival aligns closely with a systematic review of 809 patients that reported a pooled overall survival of 33 months, and with the American RESiN registry, which reported a median of 33 months. For breast cancer, the 10.7 month result is comparable to a meta-analysis of 452 patients that found a median of 11.3 months. In melanoma, where nearly 60 percent of the study’s patients received TARE as first-line liver-directed therapy, the 14.7 month median sits comfortably within the 9 to 24 month range reported across systematic reviews of radioembolization for uveal melanoma. The pancreatic cancer result, while bleak, reflects a disease in which even surgery and modern chemotherapy yield median survivals under a year in the metastatic liver setting.

The study’s authors are careful about its limits. As an observational registry without a control group, it cannot prove that TARE is superior to other options, and selection bias and residual confounding cannot be excluded. The lack of a standardized treatment protocol across 27 centers introduced heterogeneity in baseline characteristics, treatment timing, and surrounding systemic therapies. Missing data may have affected some analyses, and no multivariable model was possible for the pancreatic cohort because too few variables reached the significance threshold. What the study does provide is something rarer: prospectively collected, multicenter, real-world evidence about how TARE is actually used and how patients actually fare when multidisciplinary teams choose it for tumors that fall outside existing guidelines.

That guideline gap is precisely why the results matter. TARE is a standard of care for intermediate to advanced hepatocellular carcinoma and for metastatic colorectal cancer, but for non-colorectal liver metastases, formal recommendations have been largely absent; the European Neuroendocrine Tumour Society recently noted that no data existed on liver embolization for neuroendocrine carcinoma. By documenting safety and encouraging effectiveness in 169 patients across four tumor types, the CIRT analysis gives clinicians a firmer evidence footing for a treatment many were already offering, and it sets a clear agenda: prospective comparative studies are now needed to identify which patient groups benefit most, and simple markers like ALBI and APRI may help decide who should be offered the radioactive beads and who should be spared the procedure.

Subject of Research: Yttrium-90 transarterial radioembolization for non-colorectal liver metastases

Article Title: Transarterial radioembolization for liver metastases of non-colorectal origin: safety and effectiveness results from the prospective multicenter CIRSE registry for SIR-spheres therapy (CIRT)

Article References: Arnold, D., Chlorogiannis, D. D., Sangro, B., Kolligs, F., Maleux, G., Bilbao, J. I., Pech, M., Pfammatter, T., de Jong, N., Geyer, M., Urdániz, M., & Helmberger, T. (2026). Transarterial radioembolization for liver metastases of non-colorectal origin: safety and effectiveness results from the prospective multicenter CIRSE registry for SIR-spheres therapy (CIRT). CVIR Oncology, 2(1), Article 6. https://doi.org/10.1007/s44343-026-00039-1

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00039-1

Keywords: transarterial radioembolization, yttrium-90, liver metastases, neuroendocrine tumors, breast cancer, pancreatic cancer, melanoma, SIR-Spheres, CIRT registry, ALBI grade, APRI, interventional radiology

The central problem these devices address is a matter of fluid dynamics. Blood, and everything carried within it, flows from regions of higher pressure to regions of lower pressure. Liver tumors are fed by hepatic arteries, and in theory their leaky, metabolically hungry new vessels should siphon a disproportionate share of any intra-arterial infusion. In practice, tumor vasculature is chaotically organized, with irregular branching, avascular dead zones, and elevated interstitial pressure generated by an expanding extracellular matrix and cytokines produced by malignant cells. This pressure, which can be worse at the tumor core and may even equal or exceed intravascular pressure, collapses vessels and blocks homogeneous delivery of therapies. The result is a positively reinforced cycle: hypoxia from poor perfusion triggers more cytokine release, more matrix deposition, higher interstitial pressure, and still worse perfusion, leaving parts of the tumor effectively unreachable.

The idea of intervening on pressure is not new. In 1991, Nakamura and colleagues used a balloon catheter to redirect blood flow away from gastric branches and toward normal liver parenchyma to prevent non-target embolization. The concept then lay largely dormant until Irie and colleagues revived it around the turn of the century, noticing that balloon-occluded chemoembolization produced markedly denser ethiodized oil staining within tumors, even when non-target embolization was not a concern. Crucially, later work showed that flow redistribution did not occur in patients who lacked a reduction in pressure at the catheter tip, a finding that shifted attention from simple anti-reflux protection to the hemodynamic consequences of lowering downstream arterial pressure. Microvalve technology, developed initially to prevent reflux, was subsequently found to reduce downstream compartmental pressure as well.

The review organizes the mechanisms into two complementary categories: mechanical and pressure-related, or physiologic. On the mechanical side, both balloon and microvalve catheters prevent reflux of embolic material, which has two consequences. First, more embolic can be delivered before arterial stasis, the point at which downstream pressure equals inflow pressure, at which a traditional end-hole catheter simply pushes material back into non-target vessels. In a porcine model, Arepally and colleagues showed that a microvalve system increased on-target embolization efficiency from 72 percent to 99.9 percent. Irie’s group demonstrated that balloon occlusion allowed 270 percent more ethiodized oil to be delivered during chemoembolization compared with a standard microcatheter. Anti-reflux protection can also reverse normal hepatic arterial flow from a proximal delivery point, shielding normal liver downstream of the balloon, and can eliminate the need for prophylactic coil embolization of at-risk vessels such as the gastroduodenal artery.

Second, mechanical centering matters more than intuition might suggest. As a catheter is advanced through tortuous arteries, its tip rarely sits in the center of the vessel lumen, and computational fluid dynamics studies have found non-centro-luminal positioning in up to 71 percent of experiments. A radial tip displacement as small as 1.5 millimeters can cause deviations of up to 53 percent from homogeneous particle delivery, biasing embolic flow preferentially toward one branch at bifurcations. Balloon and microvalve catheters, by virtue of their wall apposition when deployed, promote centro-luminal positioning. Microvalve catheters go further: because they preserve antegrade flow, the valve opening and closing through the cardiac cycle creates turbulence that homogenizes the embolisate before it flows distally. A bench-top model showed that a microvalve device reduced deviation from homogeneous delivery from 41 percent to 15.5 percent compared with an end-hole catheter, and a separate flow study found that continuous homogeneous delivery produced roughly threefold greater distal microsphere penetration than conventional bolus injection by preventing proximal clumping.

The physiologic mechanisms may be even more interesting. Unlike tumor vessels, which are immature and lack normal smooth muscle and innervation, normal hepatic arteries constrict in response to vasoactive stimuli. Pressure-modifying catheters lower the arterial pressure in the downstream compartment, prompting constriction of normal liver vasculature attempting to maintain perfusion while leaving the unresponsive tumor vessels unaffected, thereby shifting the fractional blood flow toward the tumor. This mimics pharmacologic strategies: a systematic review found that infusing angiotensin II before radioembolization increased the tumor-to-normal liver ratio in every study reviewed, with median improvements ranging from 1.8- to 3.1-fold, and vasopressin produced concordant results in a porcine model.

The clinical evidence, however, is genuinely mixed, and the authors are candid about this. In a randomized controlled trial of a microvalve infusion system during holmium-166 radioembolization, van Roekel and colleagues found no difference in tumor-to-non-tumor ratios or response rates, possibly because the investigators prophylactically infused nitroglycerin through the catheter to guard against vasospasm, which would have preferentially dilated normal liver vessels and negated the physiologic effect. In contrast, d’Abadie and colleagues, who did not regularly use vasodilators, found statistically significant improvements in tumor-to-normal ratio and absorbed dose with an antireflux catheter, with effects most pronounced in hypervascular tumors such as neuroendocrine tumors and hepatocellular carcinoma rather than hypovascular colorectal metastases. Pasciak and colleagues, in an intra-patient randomized pilot, demonstrated increased tumor uptake and decreased normal liver uptake with a microvalve catheter, while Lucatelli’s group reported a 46 percent increase in tumor dose with balloon-occluded radioembolization in hepatocellular carcinoma.

Two further mechanisms round out the picture. Lowered downstream pressure appears to recruit and reverse flow within intrahepatic arterial collaterals, shunting blood hepatopedally toward the tumor; Rose and colleagues demonstrated reproducible pressure drops distal to the catheter tip across vessel sizes and catheter types, and Matsumoto’s work identified specific hepatic territories where insufficient stump pressure reduction predicts lack of benefit. Separately, preclinical work by Johnson and colleagues showed that even at angiographic stasis, up to 44 percent of tumor vessels remained patent, intermittently recruited during embolization. Transient pressure augmentation during bolus infusion may force embolic material past interstitial pressures that normally occlude these vessels, driving penetration into the poorly vascularized tumor core. Jaroch’s porcine studies confirmed increased delivery throughout the tumor, including its core, with microvalve catheters even with minimally embolic glass microspheres, and Titano and colleagues found that microvalve catheters improved objective response rates and explant necrosis in drug-eluting bead chemoembolization despite lower drug amounts being delivered.

The review is equally clear about the limits of the evidence. Most supporting data come from preclinical models, bench-top flow systems, computational simulations, small retrospective cohorts, and single-center experiences, often relying on surrogate endpoints such as lipiodol deposition, uptake ratios, and absorbed dose rather than survival or toxicity. The authors also emphasize practical caveats: balloon occlusion eliminates antegrade flow and may hinder particle mixing, microvalves produce smaller and more variable pressure changes, and the same microcatheter system should be used in both planning and treatment procedures for radioembolization. They further note that pressure modification should be interpreted differently across transarterial radioembolization, where the goal is radiobiologic dose optimization, and chemoembolization, where ischemia and lesion penetration dominate. Nevertheless, the mechanistic synthesis offers a rational framework for patient selection and procedural strategy, and the authors call for adequately powered prospective trials with standardized dosimetry and clinically meaningful endpoints to determine precisely when pressure-enabled embolization outperforms conventional delivery.

Subject of Research: Pressure-modifying catheter technology for hepatic tumor embolization

Article Title: Pressure modification during hepatic tumor embolization: principles, mechanism of action, and current evidence

Article References: Berman, Z. T., & Krishnasamy, V. P. (2026). Pressure modification during hepatic tumor embolization: principles, mechanism of action, and current evidence. CVIR Oncology, 2(1), Article 11. https://doi.org/10.1007/s44343-026-00044-4

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00044-4

Keywords: hepatic tumor embolization, pressure-modifying catheters, balloon microcatheter, microvalve, transarterial radioembolization, chemoembolization, tumor-to-normal ratio, anti-reflux, flow redistribution, interventional radiology, liver cancer, embolic delivery

TARE has become a mainstay of modern liver cancer care because of its unusual elegance. Rather than flooding the whole body with chemotherapy, clinicians deliver yttrium-90, a beta-emitting isotope bound to glass or resin microspheres roughly the width of a red blood cell, directly into the arteries that feed the tumor. The spheres lodge in the small vessels surrounding the malignancy and bathe it in high-dose radiation while sparing most healthy tissue. The technique works across the full spectrum of liver cancer severity, from early-stage disease where it can bridge patients to transplant, to advanced stages where it serves primarily to control tumor growth. Its safety record is genuinely impressive: serious adverse events occur in only about nine percent of patients, and vascular injury is estimated at no more than one percent of cases, typically arising when arterial anatomy is unusually complex, vessels have been weakened by prior chemotherapy, or pre-existing vascular abnormalities are present.

The Swiss case began conventionally enough. The patient, a man in his early seventies with liver fibrosis caused by chronic hepatitis C, was found on ultrasound to have a thirty-millimeter lesion in segment VIII of the liver, near the organ’s central hilum where major bile ducts and blood vessels converge. Magnetic resonance imaging and biopsy confirmed a moderately differentiated hepatocellular carcinoma, staged at an early BCLC stage with well-preserved liver function. A multidisciplinary tumor board weighed the options carefully. Percutaneous ablation, usually the first choice for small tumors, was judged too risky because of the lesion’s close proximity to a portal vein branch and the biliary tree. The team instead selected TARE, planning a curative dose of yttrium-90 glass microspheres engineered to deliver an estimated 324 gray to the perfused liver and more than a thousand gray to the tumor itself.

The workup phase went smoothly. Angiography revealed an anatomical quirk, a common hepatic artery arising from the superior mesenteric artery rather than its usual origin, but the team successfully navigated the tortuous route, advanced a microcatheter into the anterior sectoral artery supplying the tumor, and confirmed excellent targeting with technetium-99m-labeled macroaggregated albumin, the standard pre-treatment tracer. Two weeks later, during the therapeutic session, the trouble started. As the microcatheter was advanced along the same vessel, it caused a focal iatrogenic dissection, a tear in the arterial lining that separated the vessel wall into a true lumen and a false channel. Dissections of this kind are a recognized hazard of catheter work; guidelines from the Society of Interventional Radiology suggest they should prevent completion of the intended treatment in fewer than one percent of cases.

The team responded with textbook technique. They swapped the stiffer 2.7 French microcatheter for a softer, more flexible 1.98 French device paired with a fine guidewire, and successfully re-entered the true lumen. Digital subtraction angiography visualized the dissection, but selective intra-arterial CT angiography, a more detailed cross-sectional view taken from inside the vessel, showed no contrast stagnation in the false lumen, no pooling around the catheter tip, and preserved tumor enhancement that looked essentially identical to the simulation phase. Encouraged by these images, the physicians proceeded and administered 2.9 gigabecquerels of yttrium-90. Only afterward did post-treatment positron emission tomography reveal the flaw in that confidence: focal radioactive tracer uptake outside the liver tissue, in the region of the hepatic hilum, exactly where the dissection had occurred. Dosimetry calculations estimated that some 678 gray of radiation, an extraordinary dose by any standard, had pooled on the damaged arterial wall.

The critical insight, one the authors emphasize with some force, is that contrast dye is not a reliable proxy for microsphere behavior. Contrast agents and yttrium-90 spheres differ in particle size, density, and the way they move with blood flow, so a vessel that appears well perfused on angiography can still trap radioactive particles unevenly. In this patient, the dissection created abnormal flow conditions at the hepatic hilum that the intraprocedural imaging could not fully resolve. The spheres that should have been distributed throughout the tumor instead accumulated along an injured arterial wall, setting the stage for a form of collateral damage that is rarely reported and poorly understood: radiation-induced arteritis of the liver’s major vessels.

Because the patient remained symptom-free, he was discharged with daily telephone monitoring and a scheduled CT angiography seven days later, a deliberate precaution given the enormous extraparenchymal dose. That scan proved decisive. It revealed diffuse arteriopathy involving the common, right, and left hepatic arteries and their proximal branches, with multiple wall irregularities and three pseudoaneurysms, the largest measuring seven millimeters in the right hepatic artery. Pseudoaneurysms are balloon-like outpouchings formed when a weakened vessel wall balloons outward under pressure, and their rupture can trigger catastrophic intra-abdominal hemorrhage. The rapid onset of these changes, detectable within a single week, suggested a sinister synergy: mechanical injury from the catheter tearing the intima, compounded almost immediately by yttrium-90 radiation destroying the endothelial cells and muscular media of the vessel wall beneath.

The pathophysiology of radiation-induced vascular injury has been studied mostly in the context of external beam radiotherapy, where it is known to involve endothelial cell death, necrosis of the arterial media, and scarring of the adventitia that progressively narrows vessels or erodes them into aneurysms. Whether the same mechanisms unfold in the intrahepatic circulation after internal radiation has been largely uncharted territory. To the authors’ knowledge, no previous case has documented an iatrogenic arterial dissection during TARE evolving into subacute radiation-associated arteriopathy, which is precisely what makes the report valuable and unsettling. After urgent multidisciplinary consultation and shared decision-making with the patient, the team performed prophylactic coil embolization, deploying a series of detachable and pushable platinum coils through the hepatic arteries to pack shut the abnormal segments. Because the pathology was diffuse and multifocal, a covered stent, which would have preserved the vessel while sealing it, was not feasible, so the physicians accepted permanent sacrifice of the arterial tree. The patient’s preserved Child-Pugh A liver function and compensatory portal venous blood supply made the risk acceptable, though the team openly acknowledged a sobering trade-off: closing these arteries eliminated any possibility of future endovascular treatments if the cancer returned.

The outcome was, by any measure, a success story wrapped around a cautionary tale. Final angiography confirmed complete exclusion of the pseudoaneurysms and abnormal vessels, and transiently elevated liver enzymes normalized within five days. Magnetic resonance imaging at four weeks and three months showed a complete response of the original tumor by RECIST 1.1 criteria, with no biliary injury or hepatic ischemia, and preserved liver function throughout follow-up. A small new lesion in a distant segment was later treated successfully with percutaneous radiofrequency ablation. The authors distill the experience into several key lessons: anticipate vascular injury in patients with complex anatomy, reconsider microsphere delivery whenever arterial dissection occurs, maintain close post-procedural surveillance to catch vascular complications early, and weigh carefully whether definitive arterial embolization forecloses future treatment options. In asymptomatic patients, surveillance alone may suffice, since small pseudoaneurysms can stabilize or resolve, but their natural history is unpredictable and rupture can be lethal, so management must be individualized. For a procedure performed tens of thousands of times each year, this single case is a powerful reminder that even a one-percent risk deserves a protocol, and that the liver’s arteries, once injured and then irradiated, can fail in ways we are only beginning to describe.

Subject of Research: Iatrogenic arterial dissection during transarterial radioembolization leading to radiation-induced hepatic arteritis

Article Title: Iatrogenic arterial dissection leading to radiation induced arteritis following transarterial radioembolization

Article References: Adami, M., Boughdad, S., Villard, N., Schaefer, N., Rafael, D., & Tsoumakidou, G. (2026). Iatrogenic arterial dissection leading to radiation induced arteritis following transarterial radioembolization. CVIR Oncology, 2(1), Article 25. https://doi.org/10.1007/s44343-026-00061-3

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00061-3

Keywords: transarterial radioembolization, hepatocellular carcinoma, yttrium-90, arterial dissection, radiation-induced arteritis, hepatic artery, pseudoaneurysm, coil embolization, interventional radiology, dosimetry, vascular complication, case report

The research, published in CVIR Oncology, examined whether balloon-occlusion microcatheters could improve tumor targeting during holmium-166 radioembolization. These devices carry a small inflatable balloon near their tip. When inflated inside a hepatic artery branch, the balloon temporarily halts blood flow beyond it, creating a zone of static flow arrest that proponents believe should push injected microspheres deeper into the tumor bed while preventing reflux back toward healthy liver. The idea has gained traction in transarterial chemoembolization, where several studies have reported better tumor control when the balloon is deployed. But rigorous, head-to-head evidence in radioembolization, where the physics of microsphere delivery matters just as much, has remained scarce.

What makes the Leuven study unusual, and scientifically valuable, is its within-patient design. Seven patients with unresectable primary liver tumors, six with hepatocellular carcinoma and one with hepatic angiosarcoma, each received two separate scout injections of holmium-166 microspheres at exactly the same arterial sites. The first scout dose, delivered during the standard work-up roughly two weeks before treatment, used a conventional end-hole catheter. The second, performed on the day of treatment, used an inflated balloon-occlusion catheter positioned at the identical location, with matching injection pressures, microsphere numbers, and imaging protocols. Because holmium-166 scouts and therapeutic doses use identical poly-L-lactic acid microspheres, the researchers could isolate the effect of the catheter itself with unusual precision, avoiding the confounding that arises when technetium-99m macroaggregated albumin, a particle with different size and shape characteristics, is used as a proxy.

After each scout injection, the team acquired single-photon emission computed tomography combined with CT to map exactly where the radioactive microspheres had settled. Their primary endpoint was the tumor-to-normal liver uptake ratio, a key measure of targeting quality that predicts whether a tumor receives a tumoricidal dose. The result ran counter to expectations. In six of the seven patients, the balloon catheter produced a lower tumor-to-normal liver uptake ratio than the conventional catheter. The median ratio fell from 3.1 with the conventional device to 1.7 with the balloon, a geometric mean ratio of 0.41. While this comparison did not reach conventional statistical significance with only seven pairs, the pattern was remarkably consistent, and a binomial test of the six-to-one split did reach significance.

Cone-beam CT scans told an equally sobering story. In six patients, the balloon catheter shrank the measured liver perfusion territory by between 7 and 60 percent compared with the conventional catheter. On its face, a tighter perfusion territory might sound like an improvement, suggesting more selective delivery. But in all six of those patients, the contracted territory no longer encompassed the entire tumor, leaving parts of the malignancy outside the treated zone. In one striking case, the balloon catheter actually raised the tumor-to-normal liver ratio while coverage of the tumor dropped to just 63 percent, a combination that could concentrate radiation in a fraction of the lesion while leaving the rest untreated. Because the balloon consistently produced lower targeting ratios or incomplete coverage, the treating physicians selected the conventional catheter for every therapeutic delivery.

Why would a device designed to improve targeting do the opposite? The researchers point to the distinctive hemodynamics of balloon occlusion. Unlike pressure-enabled drug delivery systems, which preserve forward flow through a one-way valve while blocking reflux, a balloon catheter creates abrupt static flow arrest and a pronounced pressure drop downstream of the balloon. The liver’s arterial anatomy is richly interconnected, with communicating arcades linking segments and even lobes. When the balloon cuts off flow at one branch, blood finds its way back into the occluded territory through these collaterals, and the redirected inflow can carry microspheres away from the intended target. Tumors situated at the boundary between adjacent vascular territories, so-called watershed tumors, are particularly vulnerable, because their arterial supply may come from more than one feeder artery and flow modulation at a single injection site leaves portions of the lesion poorly perfused.

The injection protocol may also have played a role. Holmium-166 scout doses at Leuven are delivered through a standardized low-pressure administration box designed to prevent overpressurization of the vial, a safety necessity for the radioactive microsphere system. That low-pressure regimen contrasts with balloon-assisted chemoembolization, where operators can push high injection pressures through a syringe mounted directly on the catheter, potentially overcoming watershed effects. Bench testing confirmed the balloon catheter’s pressure profile closely matched that of the conventional catheter, so the team attributes the lower targeting ratios not to injection mechanics but to genuine alterations in intrahepatic flow dynamics caused by the occluding balloon itself.

The study’s authors are careful about how far these conclusions travel. The trial was terminated early after seven patients when the QuiremScout and QuiremSpheres platform was discontinued, and all scout injections followed the same fixed order, meaning an order effect from the first microsphere injection, though unlikely given published concordance between scout and therapeutic distributions, cannot be fully excluded. The patient mix also included several watershed tumors that were never ideal balloon candidates, and one patient had an angiosarcoma, complicating flow analysis. The findings characterize holmium-166 scout distribution under a low-pressure protocol and may not extend to yttrium-90 platforms, alternative delivery systems permitting higher pressures, or dynamic antireflux devices, which preclinical work suggests could behave quite differently.

There is also a broader lesson about measurement. A tumor-to-normal liver uptake ratio on its own, the authors argue, is an incomplete yardstick, because a high ratio achieved at the cost of partial tumor coverage can be actively harmful. They propose judging targeting quality as a composite of the ratio, the completeness of tumor coverage, and the exposure of non-tumoral parenchyma, an approach made practical by dual-phase cone-beam CT, which can map arterial perfusion territories far more accurately than conventional anatomical segmentation. For now, the message for clinicians is one of caution rather than condemnation: the benefit of balloon-occlusion microcatheters in radioembolization cannot be assumed, and appears to depend heavily on each patient’s vascular anatomy. Larger, randomized studies with sequence inversion, ideally comparing across microsphere platforms, delivery systems, and injection pressures, will be needed to determine whether flow modulation earns a place in the radioembolization toolkit, or whether the humble end-hole catheter, in most patients, still delivers the best dose to the tumor.

Holmium-166 itself deserves attention when weighing these results. The isotope emits both beta particles for therapeutic effect and gamma photons at 81 keV, which is what allows the same scout injection used for planning to be imaged quantitatively on SPECT rather than merely serving as a rough surrogate. Yttrium-90, by contrast, produces almost no useful gamma signal, so planning scans with technetium-99m macroaggregated albumin must stand in for the therapeutic agent, introducing known discrepancies in particle size, density, and flow behavior. The Leuven team’s paired design exploits this holmium advantage: because scout and therapy microspheres are chemically and physically identical, the observed differences in distribution can be attributed to the catheter and the altered hemodynamics rather than to a mismatch between tracer and treatment.

The clinical stakes of targeting quality are considerable. Absorbed tumor dose is one of the strongest predictors of response in radioembolization, while inadvertent delivery of activity to non-tumoral liver parenchyma drives the risk of radioembolization-induced liver disease, a potentially serious decline in hepatic function that is especially concerning in patients with compromised liver reserve. A tumor-to-normal liver uptake ratio that drops from above three to below two, as observed in most patients here, implies a substantial shift of activity away from the malignancy, which could translate into lower tumoricidal doses and reduced treatment efficacy if such a distribution were used for therapy.

The study also illustrates a practical constraint of radioembolization logistics that is easy to overlook. Holmium-166 decays with a half-life of about 26 hours, and therapeutic activity must be manufactured and calibrated for a pre-specified treatment time. Because the balloon-occlusion scout was performed on the treatment day itself, the prescribed activity could not be recalculated from the alternative dosimetry, meaning the final delivery necessarily followed the conventional catheter plan. This timing structure, while a limitation for flexibility, is precisely what allowed the two work-ups to be compared within the same patient under otherwise matched conditions.

Finally, the findings add to a growing recognition that flow-modulating devices are not interchangeable. Static occlusion and dynamic antireflux systems alter intrahepatic pressure and flow in fundamentally different ways, and their effects may diverge across tumor types, vascular architectures, and injection protocols. Careful per-patient evaluation, rather than blanket adoption of any single device, remains the soundest approach.

Subject of Research: The effect of balloon-occlusion microcatheters on tumor targeting in holmium-166 transarterial radioembolization.

Article Title: Effect of balloon-occlusion microcatheters on tumor targeting in holmium-166 radioembolization: a within-patient comparative study

Article References: Bonne, L., Deroose, C. M., Deckers, W., Laenen, A., Terwinghe, C., Baete, K., Verslype, C., & Maleux, G. (2026). Effect of balloon-occlusion microcatheters on tumor targeting in holmium-166 radioembolization: a within-patient comparative study. CVIR Oncology, 2(1), Article 23. https://doi.org/10.1007/s44343-026-00056-0

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00056-0

Keywords: radioembolization, holmium-166, balloon-occlusion catheter, tumor targeting, interventional radiology, liver cancer, hepatocellular carcinoma, SPECT/CT, cone-beam CT, transarterial radioembolization, microspheres, hemodynamics